MAP2K1 and infection: EGFR inhibition using gefitinib and erlotinib, or of MEK1/2 (using UO126), dose-dependently decreased the vanadate-enhanced growth of VSVΔ51 tagged with a GFP marker in 786-0 cells as determined by phase and fluorescent microscopy images captured 24 h post infection (hpi) (Figures 2B, S5, and S6).